CSL to lay off up to 15% of workforce, cut R&D costs and spin out vaccine unit - Fierce Biotech

CSL is laying off up to 15% of its workforce as the Australian pharma looks to cut R | CSL is laying off up to 15% of its workforce as the company looks to cut R&D costs and spin out its vaccine subsidiary.